SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi is investigating potential securities-law claims against ARS Pharmaceuticals (NASDAQ: SPRY) on behalf of investors who purchased shares between March 9, 2026 and June 24, 2026. A federal securities class action has been filed, and investors have until October 5, 2026 to seek appointment as lead plaintiff. The notice provides no details on the alleged misconduct, financial damages, or company response.

Analysis

This is a low-information legal-advertisement event rather than an independently validated change in SPRY's fundamentals. The near-term trading effect is mainly incremental headline and shareholder-overhang risk: retail holders may sell ahead of the October 5 lead-plaintiff deadline, while prospective institutional buyers may defer entry until the underlying allegations and any company response are clearer. Litigation itself is unlikely to be financially material for a commercial-stage biotech unless it exposes a disclosure failure that forces revised assumptions around adoption, reimbursement, safety, or regulatory durability.

The relevant catalyst path is binary and should be separated by horizon. Over days to 1-3 months, monitor whether additional firms file similar notices, whether the complaint survives dismissal, and—more importantly—whether management changes guidance or discloses facts consistent with the allegations. Over 6-18 months, any settlement is generally less important than whether the episode raises SPRY's cost of capital and limits financing flexibility; that matters disproportionately if cash runway is short relative to commercialization spending.

Consensus should not mechanically short a biotech on a plaintiff-law-firm release: these notices frequently follow a stock decline and can be reactive rather than predictive. A bearish thesis is only actionable if the litigation coincides with evidence of weakening prescription trends, payer resistance, a safety signal, or a need for dilutive capital. Conversely, confirmation that operating KPIs and cash runway remain intact could make the legal overhang a temporary liquidity dislocation rather than a fundamental impairment.

Key Decisions for Investors

• No new directional position solely on this notice. Treat SPRY as a watch item through the October 5 deadline; require the filed complaint, management response, and current cash runway before underwriting any litigation-related valuation impact.
• For existing SPRY longs, reduce gross exposure or hedge over the next 1-3 months if position size assumes uninterrupted commercial execution. A practical falsifier for maintaining exposure is any guidance cut, cash-runway deterioration, or disclosure tying allegations to prescription, payer, safety, or regulatory metrics.
• Consider a tactical short only after a failed technical rebound or verified fundamental catalyst, not on the law-firm headline. Cover if the company reaffirms operating guidance with supporting commercial data and shares recover above the post-complaint reaction high.
• If shares weaken materially without revised guidance or evidence of impaired launch metrics, evaluate a small, time-defined long after reviewing liquidity and short interest. The upside case is normalization once the deadline passes; invalidate it if financing risk rises or the court process uncovers company-specific operational facts.